Afinitor (Breast Cancer) – Analysis and Forecasts to 2020

Date: November 1, 2011
Pages: 47
Price:
US$ 2,000.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A6868452976EN
Leaflet:

Download PDF Leaflet

Afinitor (Breast Cancer) – Analysis and Forecasts to 2020
Afinitor (Breast Cancer) – Analysis and Forecasts to 2020

Summary

GlobalData’s pharmaceuticals report, “Afinitor (Breast Cancer) – Analysis and Forecasts to 2020” provides Afinitor sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Breast Cancer market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope
  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Afinitor including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Afinitor including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2013-2020 for Afinitor in the seven major markets

Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 Breast Cancer Market
2.2 Epidemiology
2.3 Etiology and Risk Factors
  2.3.1 Age and Gender
  2.3.2 Genetic Inheritance
  2.3.3 Harmonal Replacement Therapy
  2.3.4 Radiation
  2.3.5 Obesity
  2.3.6 Alcohol Consumption
  2.3.7 Late Child Birth
  2.3.8 Use of Birth Control Pills
2.4 GlobalData Report Guidance

3 BREAST CANCER: MARKET CHARACTERIZATION

3.1 Breast Cancer Market
3.2 Breast Cancer Market Forecasts and CAGR
3.3 Drivers of Breast Cancer Market
  3.3.1 High Prevalence
  3.3.2 Breast Cancer: Most Frequent Cancer in Women
  3.3.3 Increasing Breast Cancer Incidence Rate
  3.3.4 Decreasing Breast Cancer Mortality Rate
  3.3.5 High Survival Rates of Breast Cancer

4 STAGING OF BREAST CANCER: INTRODUCTION

4.1 Distribution of Patients by Stages
  4.1.1 Stages

5 PREDICTIVE BIOMARKER IN THE TREATMENT OF BREAST CANCER

6 TREATMENT OPTIONS OF BREAST CANCER

6.1 Stage 0 Breast Cancer: Treatment Options
6.2 Early Stage Breast Cancer (Excluding Stage 0)
6.3 Metastatic Breast Cancer (MBC)
  6.3.1 Endocrine Treatment: Adjuvant, First Line and Second Line
  6.3.2 Cytotoxic Chemotherapy
  6.3.3 Management of Patients with HER-2 Positive Patients

7 AFINITOR

7.1 Introduction
7.2 Mechanism of Action
7.3 Clinical Studies
  7.3.1 Phase III study to evaluate the efficacy and safety of Everolimus in Combination with Exemestane versus exemestane alone in post menopausal women with ER positive, HER2 negative metastatic breast cancer (BOLERO-2)
  7.3.2 Phase I/II trial to determine the Safety and Efficacy of everolimus (E) plus trastuzumab (T) in Patients with T-resistant Metastatic Breast Cancer
  7.3.3 Everolimus in Combination with trastuzumab and paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer (BOLERO-1)
  7.3.4 Daily everolimus in Combination with trastuzumab and vinorelbine in HER2 Positive women with Locally Advanced or Metastatic Breast Cancer (BOLERO-3)
7.4 Approval Status of Afinitor
7.5 Factors Affecting Sales of Afinitor
  7.5.1 Significant Efficacy in Combination with Hormonal Therapy
  7.5.2 Increasing Use of Targeted Therapy
  7.5.3 High Cost of Afinitor
  7.5.4 Patent Expiry of Aromasin
7.6 Drug Risk Benefit Score
  7.6.1 Relative Efficacy
  7.6.2 Safety
  7.6.3 Compliance
  7.6.4 Dosing Convenience
7.7 Intensity of Competition
7.8 Sales Forecasts
  7.8.1 Target Patient Pool of Afinitor
  7.8.2 Dosing
  7.8.3 Market Penetration
  7.8.4 Annual Cost of Therapy
  7.8.5 Sales Projections of Afinitor

8 APPENDIX

8.1 Market Definitions
8.2 Abbreviations
8.3 Research Methodology
  8.3.1 Coverage
  8.3.2 Secondary Research
  8.3.3 Forecasting
  8.3.4 Number of Patients Approved to take the Drug
  8.3.5 Net Penetration of Drug
  8.3.6 Net Annual Dosing
  8.3.7 Annual Cost of Therapy
  8.3.8 Primary Research
  8.3.9 Expert Panels
8.4 Drug Sales Estimates Model
8.5 Contact Us
8.6 Disclaimer
8.7 Sources

LIST OF TABLES

Table 1: Breast Cancer, Incidences and Mortality, By Country, 2008-2030
Table 2: Five-Year Relative Survival Rates, By Stages
Table 3: Approval Status of Afinitor
Table 4: Drug Risk Benefit Score (DRB) Afinitor
Table 5: Estimated Annual Cost of Therapy of Afinitor, 2013
Table 6: Afinitor, Breast Cancer, Global, Sales Forecasts ($m), 2013–2020
Table 7: Afinitor, Breast Cancer, the US, Sales Forecasts ($m), 2013–2020
Table 8: Afinitor, Breast Cancer, the UK, Sales Forecasts ($m), 2013–2020
Table 9: Afinitor, Breast Cancer, France, Sales Forecasts ($m), 2013–2020
Table 10: Afinitor, Breast Cancer, Germany, Sales Forecasts ($m), 2013–2020
Table 11: Afinitor, Breast Cancer, Italy, Sales Forecasts ($m), 2013–2020
Table 12: Afinitor, Breast Cancer, Spain, Sales Forecasts ($m), 2013–2020
Table 13: Afinitor, Breast Cancer, Japan, Sales Forecasts ($m), 2013–2020

LIST OF FIGURES

Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010
Figure 2: Breast Cancer, Global, Market Size Forecasts ($bn), 2010–2020
Figure 3: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005
Figure 4: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005
Figure 5: Breast Cancer, Incidence, Worldwide, 2008-2030
Figure 6: All Cancers, Incidence, Worldwide, 2008-2030
Figure 7: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005
Figure 8: Breast Cancer, Mortality, Worldwide, 2008-2030
Figure 9: All Cancers, Mortality, Worldwide, 2008-2030
Figure 10: Broad Classification of Breast Cancer, By Type
Figure 11: Classification of Non-Invasive Breast Cancer, By CIS
Figure 12: Classification of Invasive Breast Cancer, By Stages
Figure 13: Classification of Invasive Breast Cancer, By Treatment
Figure 14: Classification of Metastatic or Advanced Breast Cancer
Figure 15: Metastatic Breast Cancer Classification
Figure 16: Current Molecular Biomarkers used in the Clinical Management of Breast Cancer
Figure 17: Breast Cancer Intrinsic Sub Types used for Deciding Treatment Options for MBC
Figure 18: Breast Cancer Types in Decreasing Order of their Aggressiveness
Figure 19: Treatment Options, DCIS Breast Cancer
Figure 20: Treatment Options, LCIS Breast Cancer
Figure 21: Treatment Options, Stages I, II and IIIA
Figure 22: Treatment Options, Stages I, II and IIIA (HR Positive and Premenopausal Breast Cancer)
Figure 23: Treatment Options, Stages I, II and IIIA (HR Negative, Pre and Postmenopausal Breast Cancer)
Figure 24: Treatment Options, Stages I, II and IIIA (HR Positive Postmenopausal Breast Cancer)
Figure 25: Adjuvant Therapy for HR Positive, HER2 Negative Metastatic Breast Cancer
Figure 26: Hormonal Therapy in Adjuvant Setting in HR Positive, HER2 Negative MBC
Figure 27: Adjuvant and First Line Therapy for HR Negative, HER2 Negative Metastatic Breast Cancer
Figure 28: Treatment Options, HR Negative and HER2 Positive Metastatic Breast Cancer
Figure 29: Drug Model Diagram of Afinitor in the US, EU and Japan
Figure 30: Afinitor, Breast Cancer, Global, Sales Forecasts ($m), 2013–2020
Figure 31: Afinitor, Breast Cancer, the US, Sales Forecasts ($m), 2013–2020
Figure 32: Afinitor, Breast Cancer, the UK, Sales Forecasts ($m), 2013–2020
Figure 33: Afinitor, Breast Cancer, France, Sales Forecasts ($m), 2013–2020
Figure 34: Afinitor, Breast Cancer, Germany, Sales Forecasts ($m), 2013–2020
Figure 35: Afinitor, Breast Cancer, Italy, Sales Forecasts ($m), 2013–2020
Figure 36: Afinitor, Breast Cancer, Spain, Sales Forecasts ($m), 2013–2020
Figure 37: Afinitor, Breast Cancer, Japan, Sales Forecasts ($m), 2013-2020
Figure 38: Afinitor, Breast Cancer, Global, Sales Distribution by Country ($m), 2019
Figure 39: Drug Model Diagram
Figure 40: Patients Approved to take the Drug

Ask Your Question

Afinitor (Breast Cancer) – Analysis and Forecasts to 2020
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: